BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 20201945)

  • 1. Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe.
    Qureshi A; Mitchell C; Richards S; Vora A; Goulden N
    Br J Haematol; 2010 May; 149(3):410-3. PubMed ID: 20201945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TropicALL study: Thromboprophylaxis in Children treated for Acute Lymphoblastic Leukemia with Low-molecular-weight heparin: a multicenter randomized controlled trial.
    Klaassen ILM; Lauw MN; van de Wetering MD; Biemond BJ; Middeldorp S; Abbink FCH; Bierings M; Te Loo DMMW; Pieters R; van der Sluis IM; Tissing WJE; Michel Zwaan C; Heleen van Ommen C
    BMC Pediatr; 2017 May; 17(1):122. PubMed ID: 28486976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Symptomatic Cerebral Sinovenous Thrombosis Associated With L-Asparaginase In Children With Acute Lymphoblastic Leukemia: A Single Institution Experience Over 17 Years.
    Malhotra P; Jain S; Kapoor G
    J Pediatr Hematol Oncol; 2018 Oct; 40(7):e450-e453. PubMed ID: 29554021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Venous thrombosis as a complication of L-asparaginase treatment in a child].
    Martínez León MI; Alonso Murciano A
    Radiologia; 2012; 54(4):372-4. PubMed ID: 21724215
    [No Abstract]   [Full Text] [Related]  

  • 5. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols.
    Grace RF; Dahlberg SE; Neuberg D; Sallan SE; Connors JM; Neufeld EJ; Deangelo DJ; Silverman LB
    Br J Haematol; 2011 Feb; 152(4):452-9. PubMed ID: 21210774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol.
    Raja RA; Schmiegelow K; Albertsen BK; Prunsild K; Zeller B; Vaitkeviciene G; Abrahamsson J; Heyman M; Taskinen M; Harila-Saari A; Kanerva J; Frandsen TL;
    Br J Haematol; 2014 Apr; 165(1):126-33. PubMed ID: 24428625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different profile of thrombin generation in children with acute lymphoblastic leukaemia treated with native or pegylated asparaginase: A cohort study.
    Rozen L; Noubouossie D; Dedeken L; Huybrechts S; Lê PQ; Ferster A; Demulder A
    Pediatr Blood Cancer; 2017 Feb; 64(2):294-301. PubMed ID: 27605400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience.
    Couturier MA; Huguet F; Chevallier P; Suarez F; Thomas X; Escoffre-Barbe M; Cacheux V; Pignon JM; Bonmati C; Sanhes L; Bories P; Daguindau E; Dorvaux V; Reman O; Frayfer J; Orvain C; Lhéritier V; Ifrah N; Dombret H; Hunault-Berger M; Tanguy-Schmidt A
    Am J Hematol; 2015 Nov; 90(11):986-91. PubMed ID: 26214580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
    Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venous thromboembolism following L-asparaginase treatment for lymphoid malignancies in Korea.
    Lee JH; Lee J; Yhim HY; Oh D; Bang SM
    J Thromb Haemost; 2017 Apr; 15(4):655-661. PubMed ID: 28150907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.
    Henriksen LT; Nersting J; Raja RA; Frandsen TL; Rosthøj S; Schrøder H; Albertsen BK;
    Br J Haematol; 2014 Jul; 166(2):213-20. PubMed ID: 24702187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study.
    Abshire TC; Pollock BH; Billett AL; Bradley P; Buchanan GR
    Blood; 2000 Sep; 96(5):1709-15. PubMed ID: 10961868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia.
    Kieslich M; Porto L; Lanfermann H; Jacobi G; Schwabe D; Böhles H
    J Pediatr Hematol Oncol; 2003 Jun; 25(6):484-7. PubMed ID: 12794528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study.
    Mitchell L; Andrew M; Hanna K; Abshire T; Halton J; Wu J; Anderson R; Cherrick I; Desai S; Mahoney D; McCusker P; Chait P; Abdolell M; de Veber G; Mikulis D
    Thromb Haemost; 2003 Aug; 90(2):235-44. PubMed ID: 12888870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
    Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
    Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4.
    Angiolillo AL; Schore RJ; Devidas M; Borowitz MJ; Carroll AJ; Gastier-Foster JM; Heerema NA; Keilani T; Lane AR; Loh ML; Reaman GH; Adamson PC; Wood B; Wood C; Zheng HW; Raetz EA; Winick NJ; Carroll WL; Hunger SP
    J Clin Oncol; 2014 Dec; 32(34):3874-82. PubMed ID: 25348002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. L-asparaginase and venous thromboembolism in acute lymphocytic leukemia.
    Goyal G; Bhatt VR
    Future Oncol; 2015; 11(17):2459-70. PubMed ID: 26274336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of thrombosis in pediatric ALL patients--is there a problem!
    Mathew P
    Vnitr Lek; 2006 Mar; 52 Suppl 1():132-3. PubMed ID: 16637462
    [No Abstract]   [Full Text] [Related]  

  • 20. Toxicity Profile of PEG-Asparaginase in Adult Patients With Acute Lymphoblastic Leukemia in Brazil: A Multicenter Cross-Sectional Study.
    Silva WFD; Massaut IHB; Bendlin RM; Rosa LI; Velloso EDRP; Rego EM; Rocha V
    Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e523-e528. PubMed ID: 32389674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.